CLSD - Clearside Biomedical, Inc.

0.41
-0.151   -36.902%

Share volume: 2,599,533
Last Updated: 11-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$0.56
-0.15
-0.27%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 13%
Liquidity 49%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
21.99%
1 Year
-58.00%
2 Year
-72.85%
Key data
Stock price
$0.41
P/E Ratio 
0.00
DAY RANGE
$0.37 - $0.58
EPS 
-$1.41
52 WEEK RANGE
$0.29 - $4.57
52 WEEK CHANGE
-$55.81
MARKET CAP 
20.779 M
YIELD 
N/A
SHARES OUTSTANDING 
5.234 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: George M. Lasezkay
Region: US
Website: clearsidebio.com
Employees: 30
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.

Recent news